Why Did Codexis (CDXS) Stock Soar Nearly 38% After Hours?

Codexis, Inc. +0.63%

Codexis, Inc.

CDXS

1.61

+0.63%

Codexis Inc. (NASDAQ:CDXS) shares surged 37.8% in after-hours trading on Wednesday to $1.75, following the company's fourth-quarter and full-year 2025 earnings release.

Q4 Profit Swing and Revenue Beat

Codexis reported fourth-quarter net income of $9.6 million, or 11 cents per share, reversing a $10.4 million loss, or 13 cents per share, in the same period a year earlier.

Total fourth-quarter revenue increased 81% to $38.9 million, up from $21.5 million in the same quarter of 2024. The figure topped the analyst estimate of $36.82 million by 5.69%.

The biotechnology company also reported a product gross margin of 65% for the quarter, up from 63% a year earlier.

Full-Year Results and 2026 Outlook

Codexis' full-year fiscal 2025 revenues rose 19% to $70.4 million.

According to the company, net loss narrowed to $44 million, or $0.50 per share, from $65.3 million, or $0.89 per share, in 2024.

The company stated that it held $78.2 million in cash, cash equivalents and short-term investments as of Dec. 31, 2025.

Codexis guided 2026 revenues of $72 million to $76 million, with cash sufficient to fund operations through end of 2027.

The company also noted that it is targeting a pharmaceutical licensing deal in the second half of 2026.

Trading Metrics, Technical Analysis

Codexis has a market capitalization of $114.71 million and a 52-week trading range of $3.87 to $0.96.

The protein engineering company's stock has a Relative Strength Index (RSI) of 52.87.

CDXS has dropped 53.99% over the past 12 months, underscoring challenges for its longer-term outlook.

Price Action: CDXS closed Wednesday’s regular session at $1.27, up 2.42%, according to Benzinga Pro data.

Currently, the stock is positioned about 10.7% above its 52-week low, close to the bottom of its yearly range.

Benzinga's Edge Stock Rankings indicate that CDXS has a negative price trend across all time frames.

Photo Courtesy: Champ008 on Shutterstock.com

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.